This was the stock's second consecutive day of gains.

INOVIO (NASDAQ: INO) has announced notable interim findings from a Phase 1 clinical trial testing DNA-encoded monoclonal ...

INOVIO (NASDAQ: INO) has announced that it will release its fourth-quarter and year-end 2024 financial results on March 18, ...

INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today ...

Inovio Pharmaceuticals Inc. closed 86.91% short of its 52-week high of $14.75, which the company reached on April 1st.

NEW YORK, NY / ACCESS Newswire / March 13, 2025 / Bionoid Pharma, Inc. ("Bionoid") is pleased to announce the successful completion of its financial audits for the fiscal years 2022 and 2023 by ...

The Global Inhaled Nitric Oxide Market is valued at approximately USD 1.12 billion in 2023 and is projected to experience robust growth with a compound annual growth rate (CAGR) of more than 7.70% ...

Inovio Pharmaceuticals, Inc. (NASDAQ:INO – Get Free Report) has been given a consensus recommendation of “Moderate Buy” by ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Merck, also known as MSD outside the U.S. and Canada, plans to significantly expand its workforce in India, aiming for around 2,700 employees by the year's end. The company focuses on therapy areas ...

Shares of Inovio Pharmaceuticals stock opened at $1.98 on Wednesday. The company has a market capitalization of $51.68 million, a PE ratio of -0.94 and a beta of 0.89. Inovio Pharmaceuticals has a ...